SMAD4 and neoplasm: In the non-responding tumor, enrichment of the pathways 'loss of function of SMAD4 in cancer' and 'SMAD4 MH2 domain mutants in cancer' indicates that the non-responder tumor shows impaired TGFB1-related transcription initiation, which corresponds to the observed (non-responder) phenotype.